Therapeutic Advances in Endocrinology and Metabolism

Papers
(The H4-Index of Therapeutic Advances in Endocrinology and Metabolism is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging – a narrative review124
Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review114
Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults60
Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis39
The global burden of thyroid cancer in high-income Asia-Pacific: a systematic analysis of the Global Burden of Disease study33
Controversies in the management of active Charcot neuroarthropathy29
Treatment of osteoporosis in the solid organ transplant recipient: an organ-based approach26
In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity24
Differences in adherence to using removable cast walker treatment during daytime and nighttime weight-bearing activities in people with diabetes-related foot ulcers22
Novel therapeutic targets for metabolism-related diseases: proteomic Mendelian randomization and colocalization analyses22
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease21
Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system21
Update on genetics and epigenetics in metabolic associated fatty liver disease20
Effectiveness of open-source Android artificial pancreas systems for glucose management in patients with type 1 diabetes: a real-world study18
Is there a causal relationship between hypothyroidism and hyponatremia?17
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor17
Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus17
Pheochromocytoma: a changing perspective and current concepts17
0.039289951324463